Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Cytoplasmic antigens for detection of Candida

a technology of cytoplasm and antigens, applied in the field of method and a means of diagnosing candida infection, can solve the problems of few definitive clinical signs or symptoms, patients that are now surviving major injuries, and significant causes of life-threatening infections in hospital patients, and achieve the effect of simple and rapid method of diagnosis

Inactive Publication Date: 2006-05-18
ROCKEBY BIOMED LTD
View PDF14 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0011] In its most general aspect, the invention disclosed herein provides a simple and rapid method for diagnosis of Candida infection. The method of diagnosis of Candida infection may be used to screen large numbers of samples for possible infection.
[0015] Antibody levels may be measured using known techniques of immunology including enzyme-linked immunoassay (ELISA or EIA), biligand binding (sandwich technique), fluorometric assay, chemiluminescent assay, immunochromatography, radialimmunodiffusion or radioimmunoassay (RIA). ELISA, immunochromatography or chemiluminescent assay methods are particularly preferred, since these are quick, sensitive, and specific, and are readily automated for large-scale use. These methods also provide quantitative determinations.

Problems solved by technology

However, over the last few decades Candida has emerged as a significant cause of life-threatening infections in hospital patients.
Patients that are now surviving major injuries, surgery, cancers and organ transplants are vulnerable to life-threatening Candida infections.
The major problem with systemic Candida infections is that there are few definitive clinical signs or symptoms.
The high rate of mortality is largely due to the rapid onset of infection and a rapidly fatal outcome.
Without an accurate diagnosis the infection often goes unnoticed until it is too late to effectively treat.
The main difficulty in the diagnosis of Candida infections is that being a commensal, mere isolation of Candida from body surfaces, or orifices, is not diagnostic of an infection.
However, it can take several days for a culture to become positive, by then it may be too late to effectively treat the infection.
Also, false positives may occur due to contamination from superficial body sites.
However, those methods are not useful for early diagnosis.
However, as arabinitol is produced by the human body, further clinical studies have cast doubt on its value.
However, PCR has not established itself as a useful diagnostic method for Candida for the same reasons as outlined above ie Candida is a ubiquitously present microorganism and false positives, due to superficial contamination, are prevalent.
However, these assays lack either sensitivity or specificity or both.
However, as Candida is a commensal, most individuals have antibody to Candida mannan, so its usefulness in the diagnosis of systemic infection is limited.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Cytoplasmic antigens for detection of Candida
  • Cytoplasmic antigens for detection of Candida
  • Cytoplasmic antigens for detection of Candida

Examples

Experimental program
Comparison scheme
Effect test

example 1

Preparation of Candida Antigen

[0092] The following three types of Candida antigen were prepared:

[0093] 1). Cell wall antigen (including mannose);

[0094] 2). Total cytoplasmic antigen (mannose depleted); and

[0095] 3). Purified immunodominant antigen (enolase).

[0096] A clinical isolate of the Candida albicans, was obtained from a patient with vaginal thrush. The identity of the Candida species was confirmed with the use of an API 20C Auxonagram strip (API System S.A., France). The C. albicans isolate was designated KEMH5.

[0097] 200 ml YEPD culture medium (1% yeast extract, 2% peptone, 2% D-glucose) was inoculated with the isolate as a starter culture and incubated for 24 h at 30° C. with aeration. The starter culture was then used to inoculate a 10L YEPD culture incubated under similar conditions in a 23L Bio-Flo Fermenter IV System (New Brunswick Scientific, Edison, N.J.).

[0098] The Candida culture was harvested from the Bio-Flo fermenter system and separated from culture mediu...

example 2

Enzyme Linked Immunosorbent Assays (ELISAS)

[0110] A serum panel was collected from 1998 to 2000 from various patients with Candida infections. Negative control (Control) sera (n=20) were obtained from the Red Cross Blood Bank, Perth, Australia and was obtained from healthy males in the 19 to 25 year age group. Sera (n=13) from patients with recurrent vulvo vaginal candidiasis (VVC) were obtained from King Edward Memorial Hospital, Perth, Australia. Sera (n=108) from patients with oral candidiasis were obtained from Clinipath Ltd and the UWA Dental School, Perth, Australia. Sera (n=39) from patients (n=28) with systemic candidiasis were obtained from Princess Margaret Hospital, Perth, Australia and Prince of Wales Hospital, Sydney, Australia.

[0111] In the case of patients with oral and vaginal Candida infection, confirmation of infection was made by physical examination and by culture of Candida organisms from the relevant body site. In the case of patients with systemic infection,...

example 3

Clinical Evaluation in France

[0124] Clinical evaluation of the triple antigen test kit as described in Examples 1 and 2 was undertaken in the Department of Parasitology and Medical Mycology at the University of Grenoble Faculty of Medicine, Grenoble, France using stored sera.

[0125] Sera from two groups of patients were analysed: those that were blood culture positive and those that were blood culture negative. When possible, sera were taken before, at the time of and after the first day of positive blood culture to be tested. The blood culture negative group was divided into 3 subgroups: Patients that were colonised with Candida and were serology positive, patients that were colonised with Candida and were serology negative, and patients that were not colonised with Candida and serology negative. The sera were obtained from patients hospitalised between 1998 and 2000.

[0126] The triple antigen ELIZA test (“the Applicant antigen test”) was performed according to Example 2. The cut-...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
molecular weightsaaaaaaaaaa
molecular weightsaaaaaaaaaa
molecular weightsaaaaaaaaaa
Login to View More

Abstract

The present invention relates to a method and a means of diagnosing Candida infection. In particular the present invention relates to a method of diagnosing Candida infection by measuring the levels of antibody to Candida cytoplasmic antigen present in a biological sample taken from a subject at risk of, or suspected to be suffering from a Candida infection.

Description

FIELD OF THE INVENTION [0001] The present invention relates to a method and a means of diagnosing Candida infection. In particular the present invention relates to a method of diagnosing Candida infection which is both sensitive and rapid. BACKGROUND OF THE INVENTION [0002]Candida is the most commonly identified causative agent of oral or vaginal thrush. However, over the last few decades Candida has emerged as a significant cause of life-threatening infections in hospital patients. Ironically the increasing incidence of these “invasive” or “systemic”Candida infections has been advances in modern medicine. Patients that are now surviving major injuries, surgery, cancers and organ transplants are vulnerable to life-threatening Candida infections. In the United States, Candida is now the fourth most common cause of blood infections in hospitals. [0003] The major problem with systemic Candida infections is that there are few definitive clinical signs or symptoms. Treatment is largely b...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): G01N33/569G01N33/53C07K14/40G01N33/48G01N33/531G01N33/543G01N33/571G01N33/573
CPCC07K14/40G01N33/56961G01N33/571G01N2333/40A61P31/10
Inventor WARMINGTON, JOHNBALLANTYNE, DENIS
Owner ROCKEBY BIOMED LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products